Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)

Fig. 3

Early on-treatment ctDNA dynamics predicts response to ICI. a Swimmer plots display the timing of RECIST response assessment, molecular response and PFS for each patient. b Compared with DCB cohort, the ΔctDNA was significantly lower in the DCB group. The red horizontal bar represents the mean and error bar represent ±SD. c Patients with increased ctDNA had shorter PFS than those with decreased and persistently negative ctDNA (median 4.0 months versus 11.2 months versus 25.7 months). d The ΔctDNA had good sensitivity and specificity to identify patients with DCB. e Patients who achived a molecular response had longer PFS than those of non-molecular responders (median 11.5 months versus 4.0 months). DCB durable clinical benefit, Chemo chemotherapy, ICI immune checkpoint inhibitor, PR partial response, SD stable disease, PD disease progression, PFS progression-free survival. P < 0.05 represents statistical significance

Back to article page